ABVC BioPharma, Inc. (ABVC) stock
Close on Nov 12, 2026Market cap $25.68MP/E –Yield –
ABVC BioPharma, Inc. grew revenue 0.0% to $296.00K over fiscal 2025. At the latest close the market valued the company at $25.68M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $25.68M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.97
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $296.00K
- Net income
- -$3.91M
- EPS, diluted
- -$0.16
- Book value per share
- $0.49
- Diluted shares
- 27M
Trading
- Previous close
- $0.99
- Open
- $0.98
- Day's range
- $0.89 – $1.00
- Volume
- 44,185
- Average volume (20 days)
- 29,193
- Beta (5 years)
- 1.08
- 52-week range
- $0.71 – $3.06
- RSI (14 days)
- 48.4
- Volatility (1 year)
- 86.1%
- Relative volume
- 0.05×
- WACC
- 10.3%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABVC | S&P 500 | Difference | ABVC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.7% | -2.7% | +1.0 pts | ||
| 3 months | +0.4% | -1.7% | +2.1 pts | ||
| Year to date | -54.8% | +11.9% | −66.7 pts | ||
| 1 year | -67.8% | +12.0% | −79.8 pts | ||
| 3 years | -9.1% | +78.2% | −87.3 pts | -3.1% | +21.2% |
| 5 years | -97.1% | +73.2% | −170.3 pts | -50.7% | +11.6% |
| 10 years | -99.7% | +309.6% | −409.4 pts | -44.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ABVC BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Results
- Update
- Results
About ABVC BioPharma
Pharmaceutical Preparations
ABVC BioPharma, Inc. is an early-stage biotechnology enterprise that develops botanical drugs and medical devices addressing central nervous system disorders and oncology diseases. The company generates revenue by outlicensing its intellectual property and providing contract development and manufacturing organization (CDMO) services through its subsidiary BioKey, which produces active pharmaceutical ingredients, capsules, tablets, and oral liquids for clinical trials. Its development pipeline features botanical drug candidates targeting conditions such as major depressive disorder, attention-deficit hyperactivity disorder, and depression in cancer patients, alongside the Vitargus medical device for vitrectomy procedures and a commercial dietary supplement line derived from maitake mushrooms.
Company profile, executives and historyABVC BioPharma stock: common questions
What is ABVC BioPharma's stock price?
ABVC closed at $0.96 on Nov 12, 2026, down 2.87% on the day. Over the past 52 weeks it traded between $0.71 and $3.06.
What is ABVC BioPharma's market cap?
ABVC BioPharma was worth $25.68M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ABVC's P/E ratio?
ABVC BioPharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.16), so it has no meaningful P/E ratio.
How much revenue does ABVC BioPharma make?
ABVC BioPharma reported revenue of $296.00K for fiscal 2025, up 0.0% from a year earlier.
Does ABVC BioPharma pay a dividend?
No. ABVC BioPharma has not paid a cash dividend over the last twelve months.
How has ABVC stock performed over the past year?
Including dividends, ABVC returned -67.8% over the past year, against +12.0% for the S&P 500.
Who are ABVC BioPharma's competitors?
Companies most similar to ABVC BioPharma by business, industry and size include LEXX, CLNN, XTLB, RGBP, SCNX.
See a number that looks wrong?